Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Next Previous
X
Search
Trial Profile

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganitumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Vincristine
  • Indications Ewing's sarcoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 03 Dec 2024 Planned End Date changed from 22 Sep 2024 to 19 Sep 2025.
    • 04 Jun 2024 Results assessing the prognostic impact of on-treatment ctDNA burden in patients with metastatic EWS treated on COG AEWS1221, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 26 Sep 2023 Planned End Date changed from 21 Dec 2023 to 22 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top